Please assess the completion status of the following clinical trial:

Trial Title: A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is a postmenopausal female 40 to 75 years of age~* Patient has a Body Mass Index (BMI) less than or equal to 35 kg/m2~* Patient has a documented history of overactive bladder for at least 6 months prior to screening~Exclusion Criteria:~* Patient has stress or mixed incontinence~* Patient has a history of interstitial cystitis, painful bladder syndrome, or chronic pelvic pain~* Patient has a history of stroke, seizures, or major neurological disorders~* Patient has a history of fecal incontinence~* Patient has a history of continual urine leakage~* Patient has had surgery to correct stress urinary incontinence or pelvic organ prolapse within 6 months of study start~* Patient received bladder training of electrostimulation within 2 weeks of study start~* Patient requires a catheter~* Patient is taking medications that cannot be stopped for the duration of the trial including certain anticholinergics or smooth muscle relaxants~* Patient began taking tricyclic antidepressants, serotonin/norepinephrine reuptake inhibitors, calcium channel blockers, ephedrine/pseudoephedrine, or diuretic therapy less than 8 weeks before study start~* Patient has been on hormone replacement therapy for less than 12 weeks at study start~* Patient must take medication for arrhythmia~* Patient consumes more than 2 alcoholic beverages per day~* Patient consumes more than 3 servings of caffeinated beverages per day (1 serving = 120 mg caffeine)~* Patient has multiple and/or severe allergies to foods and drugs~* Patient regularly uses any illegal drugs

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Part I, Sequence 1: tolterodine tartrate crossing over to matching placebo
- 2 (Type: EXPERIMENTAL): Part I, Sequence 2: placebo crossing over to study drug 4 mg once a Day (qd)
- 3 (Type: EXPERIMENTAL): Part II, Sequence 1: study drug crossing over to placebo
- 4 (Type: EXPERIMENTAL): Part II, Sequence 2: placebo crossing over to study drug

Based on this trial design, predict the completion outcome and termination type (if applicable).